Current views on the use of interferons in the treatment of polycythaemia vera (RCD code: VIII)

Anna Prochwicz, Elżbieta Szczepanek, Dorota Krochmalczyk

Full Text:



Interferon alpha is a molecule associated with stimulation of immune system cells, resulting in an anti‐proliferative and immunomodulatory effect. It has been demonstrated that interferon reduces the number of platelets, leukocytes, and erythrocytes in patients suffering from chronic myeloproliferative diseases. In this paper, we present an overview of selected research evaluating the efficacy and adverse effects of various recombinant interferons used in the treatment of polycythaemia vera. We have analysed previously reported studies on the use of interferon. Interferon alfa‐2a was the first interferon approved for standard treatment of polycythaemia vera, while the next was pegylated interferon alfa‐2a. We also present recent results from studies on a newly modified molecule, ropeginterferon, a mono‐pegylated form of interferon alfa‐2b. Interferons reduce the number of phlebotomies required in patients with polycythaemia vera, accompanied by a resolution of typical disease symptoms. Treatment is well tolerated by the majority of patients. JRCD 2019; 4 (2):


rare disease; interferon alfa‐2a; pegylated interferon alfa‐2a; ropeginterferon; polycythaemia vera


Isaacs A, Lindenmann J, Andrewes CH. Virus interference I (1957) The interferon. Proc R Soc Lond B Biol Sci 147: 258–267.

Hasselbalch HC, Holmström MO. Perspectives on interferon‐alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure? Seminars in Immunopathology 2019; 41: 5–19.

Ludwig H, Linkesch W, Gisslinger H, et al. Interferon‐alfa corrects thrombocytosis in patients with myeloproliferative disorders. Cancer Immunol Immunother 1987; 25: 266–273.

Silver RT. Long‐term effects of the treatment of polycythemia vera with recombinant interferon‐alpha. Cancer 2006; 107: 451–458.

Moulard O, Mehta J, Olivares R, et al. Epidemiology of Myelofibrosis (MF), Polycythemia Vera (PV) and Essential Thrombocythemia (ET) in the European Union (EU). Blood 2012; 120: 1744.

Kralovics R, Passamonti F, Buser AS, et al. A gain‐of‐function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779–1790.

Rampal R, Al‐Shahrour F, Abdel‐Wahab O, et al. Integrated genomic analysis illustrates the central role of JAK‐STAT pathway activation in myeloproliferative neoplasm pathogenesis. Blood 2014; 123; 123–133.

Alessandro M. How I treat polycythemia vera. Blood 2014; 124: 3212–3220.

Kiladjian JJ, Chomienne C, Fenaux P. Interferon‐alpha therapy in bcr‐abl‐negative myeloproliferative neoplasms. Leukemia 2008; 22: 1990–1998.

Kiladjian JJ, Cassinat B, Turlure P, et al. High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha‐2a. Blood 2006; 108: 2037–2040.

Utke RC, Weis BO, Larsen TS, et al. Minimal residual disease after long‐term interferon‐alpha2 treatment: a report on hematological, molecular and histomorphological response patterns in 10 patients with essential thrombocy-themia and polycythemia vera. Leuk Lymphoma 2016; 57: 348–354.

Hasselbalch HC, Larsen TS, Riley CH, et al. Interferon‐alpha in the treatment of Philadelphia‐negative chronic myeloproliferative neoplasms. Status and perspectives. Curr Drug Targets 2011; 12: 392–419.

Foa P, Massaro P, Caldiera S, et al. Long‐term therapeutic efficacy and toxicity of recombinant interferon‐alpha 2a in polycythaemia vera. Eur J Haematol 1998; 60: 273–277.

Gilbert HS. Other secondary sequelae of treatments for myeloproliferative disorders. Semin Oncol 2002; 29: 22–27.

Tashi T, Swierczek S, Kim SJ, et al. Pegylated interferon Alfa‐2a and hydroxyurea in polycythemia vera and essential thrombocythemia: differential cellular and molecular responses. Leukemia 2018; 32: 1830–1833.

Masarova L, Patel KP, Newberry KJ, et al. Pegylated interferon alfa‐2a in patients with essential thrombocythaemia or polycythaemia vera: a post‐hoc, median 83 month follow‐up of an open‐label, phase 2 trial. Lancet Haematol 2017; 4: 165–175.

Masarova L, Yin CC, Cortes JE, et al. Histomorphological responses after therapy with pegylated interferon α‐2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV). Exp Hematol Oncol 2017; 9: 30.

Kozlowski A, Charles SA, Harris JM. Development of pegylated interferons for the treatment of chronic hepatitis C. BioDrugs 2001; 15: 419–429.

Kiladjian JJ, Cassinat B, Chevret S, et al. Pegylated interferon‐alfa‐2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood 2008; 112: 3065–3072.

Quintás‐Cardama A, Kantarjian H, Manshouri T, et al. Pegylated interferon alfa‐2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin

Oncol 2009; 27: 5418–5424.

Gisslinger H, Zagrijtschuk O, Buxhofer‐Ausch V, et al. Ropeginterferon alfa‐2b, a novel IFNα‐2b, induces high response rates with low toxicity in patients with polycythemia vera. Blood 2015; 126: 1762–1769.

Gisslinger H, Klade C, Georgiev P, et al. Comparision of long‐term efficacy and safety of ropeginterferon alfa‐2b vs HU in polycythemia vera patients aged below or above 60 years: two‐year analysis from the proud/continuation phase III trials. Abstract book of the EHA 2018; S132.



  • There are currently no refbacks.
Journal of Rare Cardiovascular Diseases (JRCD)
John Paul II Hospital in Kraków, 80 Prądnicka Str., 31-202 Kraków, Poland
Phone: +48 (12) 614 33 99, +48 (12) 614 34 88 Fax: +48 (12) 614 34 88
Published by SoftQ sp. z o.o.
ul. Oleandry 2, 30-063 Kraków, Poland
Phone: +48 (12) 444 1650 Fax: +48 (12) 444 1659